Compass Therapeutics (CMPX) AI Stock Analysis

• Market Cap: $1.10B
• Dividend Yield: N/A
• Average Volume (3M): 2.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: -100.00%
• EPS Growth: -28.79%
• Country: US
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 177,862,100
• 10 Day Avg. Volume: 2,469,140
• 30 Day Avg. Volume: 2,195,178
• PEG Ratio: -0.44
• Price to Book (P/B): 1.59
• Price to Sales (P/S): 233.89
• P/FCF Ratio: -4.43
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -12.27
• 1Y Price Target: $12.33
• Price Target Upside: 93.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $6.50 ▲(1.88% Upside)

Score reflects strong technical momentum and a positive corporate update (cash runway into 2028 and near-term pipeline catalysts), partially offset by weak underlying financial performance driven by ongoing losses and cash burn, with valuation metrics constrained by negative earnings and no dividend support.

Positive Factors

Multi-year cash runway

A cash balance near $209M with runway into 2028 materially reduces near-term dilution risk and provides the financial flexibility to advance multiple clinical programs to key readouts and regulatory inflection points, supporting strategic optionality over the next several years.

Low leverage / strong equity cushion

Very low debt relative to equity gives durable financial flexibility for a R&D-heavy biotech. This reduces solvency risk, supports funding via capital allocation or selective partnerships, and preserves capacity to invest in development or hire commercial/clinical talent.

Broad pipeline and stronger leadership

A diversified portfolio of bispecific candidates plus targeted leadership additions (commercial and medical) improves the company's ability to execute trials, design development/commercial strategies, and de-risk single-program dependency, enhancing long-term probability of successful commercialization.

Negative Factors

Persistent operating losses

Sustained multiyear losses indicate the business is pre-revenue and will remain dependent on development milestones. Until commercial products generate revenues, ongoing deficits create long-term funding pressure and increase the importance of successful trial outcomes to achieve self-sustaining operations.

Negative cash flow / rising burn

Consistent negative operating and free cash flow, with free cash flow worsening year-over-year, signals structural cash consumption from development programs. This persistent burn can deplete reserves absent financing or partnerships, elevating financing and dilution risk before revenue-generation.

Dependence on external financing

Reliance on capital markets for funding is a structural vulnerability: access to equity or partner financing is contingent on market conditions and clinical progress. This creates execution risk if markets tighten or if trial setbacks reduce investor appetite, potentially forcing dilutive financings.

Compass Therapeutics Business Overview & Revenue Model

Company Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Compass Therapeutics makes money primarily through the development and commercialization of its proprietary antibody therapeutics. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential sales of developed therapies. Significant partnerships with larger biopharmaceutical firms may provide upfront payments, milestone payments, and royalties on sales, contributing to its earnings. Additionally, as its drug candidates progress through clinical trials and receive regulatory approval, Compass Therapeutics aims to commercialize these products, either independently or through strategic alliances, to drive revenue growth.

Compass Therapeutics Financial Statement Overview

Summary

Overall financial profile is mixed: a strong, low-leverage balance sheet (debt ~$9.9M vs. equity ~$209.6M) is offset by minimal revenue and persistent losses (TTM net loss ~$65.8M) plus ongoing cash burn (TTM operating/free cash flow about -$34.2M).

Income Statement

Operating performance remains weak, with no meaningful revenue base in TTM (Trailing-Twelve-Months) and large ongoing losses (TTM net loss of ~$65.8M; EBIT of ~$71.4M). Profitability is consistently negative across the period, and 2024’s modest revenue (~$0.85M) was not enough to offset the cost structure, indicating continued reliance on external funding until commercialization ramps.

Balance Sheet

The balance sheet is a relative strength: leverage is low (TTM total debt ~$9.9M vs. equity ~$209.6M), and the company has grown its asset base over time (total assets ~$231.3M TTM vs. ~$51.9M in 2020). The key weakness is ongoing negative returns on shareholder capital (TTM return on equity about -49%), reflecting sustained losses despite a solid equity cushion.

Cash Flow

Cash generation is a clear pressure point, with negative operating and free cash flow in every period provided (TTM operating cash flow about -$34.2M; free cash flow about -$34.2M). TTM free cash flow also worsened versus the prior year (free cash flow growth around -24%), signaling a rising cash burn profile; while free cash flow tracks net losses closely, the business is not yet self-funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	850.00K	0.00	0.00	0.00	0.00
Gross Profit	0.00	850.00K	0.00	0.00	0.00	0.00
EBITDA	-68.76M	-54.87M	-48.47M	-39.75M	-80.19M	-25.41M
Net Income	-65.81M	-49.38M	-42.49M	-39.23M	-82.18M	-29.50M
Balance Sheet
Total Assets	231.26M	140.40M	156.88M	199.65M	153.76M	51.91M
Cash, Cash Equivalents and Short-Term Investments	219.90M	126.72M	152.46M	186.61M	144.51M	47.08M
Total Debt	9.87M	6.63M	1.73M	2.94M	4.04M	9.33M
Total Liabilities	21.65M	15.17M	8.34M	18.01M	13.68M	11.97M
Stockholders Equity	209.61M	125.23M	148.54M	181.64M	140.08M	39.95M
Cash Flow
Free Cash Flow	-34.22M	-44.90M	-40.65M	-34.34M	-21.23M	-26.91M
Operating Cash Flow	-34.20M	-44.85M	-40.62M	-34.13M	-19.67M	-26.80M
Investing Cash Flow	-74.56M	46.77M	26.96M	-151.20M	-1.77M	38.00K
Financing Cash Flow	128.45M	17.34M	2.94M	75.76M	118.61M	48.54M

Compass Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPX, the sentiment is Positive. The current price of 6.38 is above the 20-day moving average (MA) of 5.68, above the 50-day MA of 5.38, and above the 200-day MA of 3.59, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 62.52 is Neutral, neither overbought nor oversold. The STOCH value of 83.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMPX.

Compass Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	62 Neutral	$999.67M	13.73	66.76%	―	-10.26%	144.62%
CMPX	58 Neutral	$1.10B	-13.94	-37.82%	―	-100.00%	-28.79%
KALV	57 Neutral	$765.27M	-3.91	―	―	―	-13.14%
MNPR	53 Neutral	$450.64M	-19.58	-26.54%	―	―	-73.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GOSS	47 Neutral	$590.21M	-3.52	―	―	-58.17%	-116.24%
BCYC	45 Neutral	$456.44M	―	-34.63%	―	-23.43%	-9.84%

Compass Therapeutics Corporate Events

Compass Therapeutics details cash runway and pipeline progress

On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and marketable securities balance of about $209 million as of December 31, 2025, which it expects will fund operations into 2028, and provided a broad corporate update highlighting pipeline momentum and leadership expansion. The company said key progression-free and overall survival analyses in its Phase 2/3 COMPANION-002 trial of tovecimig in biliary tract cancer remain on track for late first quarter 2026, with additional Phase 2 monotherapy data in metastatic colorectal cancer to be showcased at the 2026 ASCO GI Cancers Symposium, where tovecimig has shown differentiated activity versus other anti-VEGF agents. Compass also detailed encouraging early clinical signals from CTX-8371, including durable responses in triple negative breast cancer and a confirmed third response in Hodgkin lymphoma, prompting cohort expansions in triple negative breast cancer and non-small cell lung cancer and exploration of potential accelerated pathways in Hodgkin lymphoma. The company plans to initiate a Phase 1 study of CTX-10726, a PD-1 x VEGF-A bispecific, in the first quarter of 2026 following promising preclinical comparisons, and to start a Phase 2 trial of CTX-471 in NCAM-expressing tumors in the first half of 2026. In parallel, Compass strengthened its senior team with the appointments of Arjun Prasad as chief commercial officer and Cynthia Sirard as chief medical officer, moves aimed at bolstering its commercial and clinical development capabilities as it advances multiple first-in-class bispecific antibodies toward potentially pivotal milestones.

The most recent analyst rating on (CMPX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Compass Therapeutics stock, see the CMPX Stock Forecast page.